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Evidence over the last two decades from a number of disciplines has solidiﬁed some fundamental
concepts in metastasis, a major contributor to cancer associated deaths. However, signiﬁcant
advances have been made in controlling this critical cellular process by focusing on targeted ther-
apy. A key set of factors associated with this invasive phenotype is the nm23 family of over twenty
metastasis-associated genes. Among the eight known isoforms, Nm23-H1 is the most studied poten-
tial anti-metastatic factor associated with human cancers. Importantly, a growing body of work has
clearly suggested a critical role for Nm23-H1 in limiting tumor cell motility and progression induced
by several tumor viruses, including Epstein–Barr virus (EBV), Kaposi’s sarcoma associated herpes
virus (KSHV) and human papilloma virus (HPV). A more in depth understanding of the interactions
between tumor viruses encoded antigens and Nm23-H1 will facilitate the elucidation of underlying
mechanism(s) which contribute to virus-associated cancers. Here, we review recent studies to
explore the molecular links between human oncogenic viruses and progression of metastasis, in
particular the deregulation of Nm23-H1 mediated suppression.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The metastatic suppressor nm23 gene family is highly con-
served among a wide variety of eukaryotic species [1,2]. To date,
eight genes have been identiﬁed in humans, namely, nm23-h1,
nm23-h2, nm23-h3, nm23-h4, nm23-h5, nm23-h6, nm23-h7, and
nm23-h8 [3–12]. However, it is yet unknown whether all nm23
family members can function as metastasis suppressors. The
two most abundantly expressed and currently studied genes are
nm23-h1 and nm23-h2 [13,14]. By utilizing somatic cell hybrid
analysis and ﬂuorescence in situ hybridization, nm23-h1 and
nm23-h2 genes were found to be located at q21.3 position on
chromosome 17 near the BRCA1 locus, which is known to be
associated with early onset of familial breast and ovarian cancers
(Fig. 1A) [15]. The corresponding proteins, Nm23-H1 and -H2
possess 88% amino acids sequence homology (Fig. 1B) [16,17],
and together, they encode the A and B subunits of nucleoside
diphosphate kinase (NDPK), a ubiquitously expressed enzyme
that transfers the terminal phosphates from ATP to deoxy nucle-
oside diphosphates (dNTPs) (Fig. 1C) [17]. The murine counter-
parts of these proteins both Nm23-M1 [18] and Nm23-M2 [19],
respectively, share approximately 95% of amino acids sequence
homology with human versions [14]. Although they are highly
homologous and form a functional enzyme together, their cellularchemical Societies. Published by E
bertson).function and sub-cellular localization are signiﬁcantly different
[20]. Since their discovery, clinical studies regarding Nm23
expression, particularly Nm23-H1, at the protein and transcript
levels in various types of cancer have been extensively reported
[21,22]. An inverse correlation between its level of expression
and the metastatic potential was observed for numerous cancers
such as breast, melanoma, ovarian, hepatocellular, esophageal,
oral squamous and colon cancer [16,23–27]. However, a positive
association between tumor aggressiveness and Nm23 expression
has also been reported for several other cancer types including
cervical, testicular, prostate, thyroid, renal cell carcinoma and
hematologic malignancies [16,28–30]. The metastasis-suppressive
function of Nm23-H1 was established by ectopically expressing
Nm23-H1 (or Nm23-M1) at physiological levels in highly aggres-
sive cancer cell lines, which exhibited reduction in their meta-
static potential [31]. However, there are numerous examples
which suggest a dual role for Nm23-H1 expression in the course
of cancer propagation. While the primary tumors are found to be
associated with an elevated expression, dramatic down-regula-
tion of Nm23-H1 expression was observed at later stages with
high metastatic activities. Altogether, this information suggests
that pathogenesis associated with Nm23-H1 regulation may be
tumor speciﬁc, and thus elucidation of the regulatory mecha-
nisms for Nm23-H1 expression would further enhance our under-
standing of Nm23-H1 associated type-speciﬁc cancer progression
and so allow for the development of novel therapeutic strategies
for metastatic cancer.lsevier B.V. All rights reserved.
Fig. 1. Nm23-H1 and -H2 represent the two best studied proteins of the human Nm23 family. (A) Both nm23-H1 and nm23-H2 mapped 4 kb apart at position q21.3 on
chromosome 17. (B) Nm23-H1 and Nm23-H2 share approximately 90% amino acids sequence homology. Sequence alignment was generated by a multiple sequence
alignment program, ClustalW (http://www.ebi.ac.uk/FTP/). Red boxes depict similar amino acid residues. (C) Nm23-H1 and -H2 encode A and B subunits, respectively, of
nucleoside diphosphate kinase (NDPK) enzyme, which transfers the terminal phosphates from a nucleoside triphosphate (NTP) to nucleoside diphosphate (NDP). They form
either homo- or hetero-hexamers of an active NDPK enzyme complex. Subsequently Nm23 transfers the phosphate moiety to another substrate protein. For example, the
kinase suppressor of Ras oncoprotein (KSR) is a substrate for the histidine kinase activity of Nm23-H1.
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According to the genomic architecture and phosphotransferase
activity, human Nm23 genes have been classiﬁed into two different
groups [32]. Group I is represented by the Nm23-H1 – H4 isoforms,
whereas group II contains the Nm23-H5 – H8 isoforms [32,33].
Group INm23proteins possess a highly conserved kinase active site.
On the other hand there is no strict conservation of the kinase site
motifs for group II proteins, and only Nm23-H6 has been reported
to display kinase activity [33]. Nm23-H1 was ﬁrst discovered as a
metastatic suppressor gene by Steeg et al. [18], and different
approaches have been employed to unravel the biochemical activi-
ties associated with Nm23-H1. Nm23-H1 is characterized by awide
variety of biological functions, including transcriptional regulation,
differentiation, proliferation, and most importantly suppression of
tumormetastasis [2]. To date, threemajor enzymatic functions have
been attributed to Nm23-H1, namely, its nucleoside diphosphate
kinase (NDPK), histidine kinase and 30-50 exonuclease activities
[31]. Besides these enzymatic activities, Nm23-H1 was shown to
bind to many cellular as well as viral antigens [34]. Although, none
of the Nm23-H1 binding partners have been subjected for clinical
testing, several have prompted new translational approaches to
metastatic disease [34,35]. The precise mechanism by which
Nm23-H1 regulates metastasis is not fully understood. Thus, a
better understanding of its structure–function relationship would
provide clues to the mechanisms regulating Nm23-H1 associated
cancer metastasis in a wide range of human cancers.
2.1. Histidine kinase activity of Nm23-H1
The histidine kinase activity has been shown to be amajor factor
in regulating its metastatic suppressive functions [36–38], asmutations in Nm23-H1 which ablate its histidine kinase activity,
such as P96S and S120G, were shown to be ineffective in cell motil-
ity-suppressing activity [36,38]. Histidine protein kinases are well
documented in prokaryotes and lower eukaryotes, where they form
the ‘two component’ signal transduction system [34,35]. A number
of molecular features clearly distinguished histidine kinases from
the conventional serine, threonine or tyrosine protein kinases. As a
histidine kinase, Nm23-H1 was ﬁrst auto-phosphorylated (referred
to as NDPK activity, see below) at histidine residue using ATP, and
subsequently transfers the phosphate moiety to another protein
on a histidine or other residue [34]. For example, the kinase suppres-
sor of Ras oncoprotein (KSR) is a substrate for the histidine kinase
activity of Nm23-H1 [38], suggesting a potential mechanism of cell
motility suppression by regulating Ras-Raf-MEK-Erk signaling cas-
cade [34]. However, a detailed characterization of downstream his-
tidine kinase substrates as well as their associations to metastasis
suppression is yet to be validated.
2.2. NDPK activity of Nm23-H1
The nucleoside diphosphate kinase (NDPK) activity of Nm23-H1
is not essential for metastasis suppression [39], although this is yet
to be validated using an over-expression system as used in deter-
mining histidine kinase activity. The human nm23-h1 gene encodes
the A subunit of NDPK that can be activated as homo or hetero-
hexamers with B subunit encoded by nm23-h2 gene [17]. A nucle-
otide trans-phosphorylation activity covalently transfers the ter-
minal phosphate from a nucleoside triphosphate to a nucleoside
diphosphate and maintains cellular homeostasis [40]. For example,
GTP is used as a source of energy for protein biosynthesis and is
essential for activation of G-protein mediated signal transduction
[41]. Nm23-H1 has explicitly been shown as a cellular GTP supplier
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recently demonstrated that the secreted NDPK-A in breast cancer
cells produced extracellular ATP which activates the PY2 receptor
[42]. This receptor is associated with neo-vascularization [42]. In
addition, Nm23-H1 can phosphorylate the aspartic acid residue
of aldolase-C, although the precise function of the phosphorylated
aldolase-C in tumor metastasis is still unclear [35].
2.3. Nuclease activity of Nm23-H1
2.3.1. Exonuclease
In contrast to histidine kinase and NDPK activities, no reports
have as yet implicated the Nm23-H1 30-50 exonuclease activity as
to a role in contributing to the metastatic potential. However, as
30-50 exonucleases are typically important for the maintenance of
genomic integrity; this activity represents a potential target for
regulating the metastasis suppressor properties of Nm23-H1. A
role for DNA repair activities in resisting cancer progression is sup-
ported indirectly by reports of accelerated mutation in highly met-
astatic clones versus weakly metastatic cells from the same tumor
cell population. Moreover, development of metastasis depends on
genetic instability of transformed cells that give rise to populations
of cells capable of metastatic spread, apparently through a Darwin-
ian-like selection process [31]. These observations suggest a novel
anti-mutator activity that mediates metastasis suppressor activity
of Nm23-H1, and that the down-regulation of Nm23-H1 may facil-
itate the spread of mutations, which are thought to be critical for
metastasis progression [31].
2.3.2. Endonuclease
Furthermore, data supporting the association of Nm23-H1 as a
constituent of the SET complex, a macromolecular complex, which
is associated with the endoplasmic reticulum and is targeted by
Granzyme-A during cytotoxic T lymphocyte induced apoptosis
was presented by the Lieberman group [43]. Granzyme-A cuts
the SET complex and subsequently activates the endonuclease
activity of Nm23-H1. The importance of Nm23-H1 and SET in
Granzyme-A -mediated cell death was conﬁrmed by ﬁnding in-
creased DNA damage and cell death in cells that over-express
Nm23-H1 or have silenced SET and, conversely, by ﬁnding less cell
death in targets with silenced Nm23-H1 or enhanced SET expres-
sion [43]. Furthermore, SET was thought to also translocate along
with Nm23-H1, to the nucleus where the complex is thenTable 1
Binding partners of Nm23-H1 and proposed biological consequences.
Binding
partners
Biological consequences
Cellular
h-prune Increases h-prune phosphodiesterase activity and cell motility. Directl
low expression of Nm23-H1 in aggressive tumor cells
STRAP Negative regulation of TGF-b mediated signaling, Increases p53 activit
KSR Direct substrate for histidine kinase activity of Nm23-H1, regulates cell
SET Formation of an inhibitory SET complex, blocks Nm23-H1 mediated ex
Rad Maintains GDP-GTP cycling, acts as a GTPase-activating protein for Ra
Tiam1 Blocks Tiam1-Rac1 mediated signaling pathway, decrease cell motility
Dbl-1 Interaction results in loss of Dbl-1 function as a guanine nucleotide ex
activity
ERa Alters estrogen-responsive gene expression
Viral
EBNA3C Promotes Nm23-H1 nuclear localization, negatively regulates the metas
Nm23-H1 can block Necdin-mediated transcriptional repression and a
Nm23-H1, EBNA3C can transcriptionally upregulate MMP-9, Cox-2 and
EBNA1 Modulates Nm23-H1 associated metastatic activities
LANA Induces Nm23-H1 nuclear translocation, re-expression of Nm23-H1 bl
inhibiting MAPK-signaling pathway
E7 Blocks granzyme A-induced apoptosis and promotes cell invasiveness bdisrupted, SET is then degraded and Nm23-H1 now released from
the complex can induce it DNA-nicking activities which leads to
genomic instability and apoptotic activities. Following Granzyme-
A treatment, the puriﬁed SET complex shows signiﬁcant exonucle-
ase activity on supercoiled plasmid DNA [44,45]. This activity could
be mediated due to both Nm23-H1 and/or TREX1, another impor-
tant 30-50 exonuclease [43]. Inclusion of TREX1 in the SET complex
was shown to be speciﬁc, since the TREX1 homolog TREX2 was not
found to be present in SET complex [43]. As similar to Nm23-H1,
TREX1 is also not a Granzyme-A substrate [43] and functions syn-
ergistically with Nm23-H1 to destroy DNA during Granzyme-A-
mediated cell death [43]. After Nm23-H1 nicks one strand, TREX1
removes bases from the free 30-end to enhance the damage and
prevents DNA end re-annealing and rapid repair [43]. Additional
studies investigating complexes which include Nm23-H1 and SET
also suggest that the observed DNA nicking activity is likely to be
of an endonuclease which is a co-purifying component of the com-
plex containing Nm23-H1 [46], and that the activity of Nm23-H1
in the complex has not been fully demonstrated.
3. Cellular binding partners of Nm23-H1
Recent insights into the ability of Nm23-H1 to interact with a
wide range of cellular proteins and manipulating multiple cellular
signaling have shed light on new avenues of research and possible
drug targets in the ﬁeld of metastasis. Nm23-H1 has been reported
to interact with many proteins, including a number of important
cellular proteins involved in critical biochemical pathways as well
as tumor virus encoded essential oncoproteins. Table 1 represents
a list of the Nm23-H1 interacting proteins thought to have the
most signiﬁcant alterations in their biological functions due to
interactions with Nm23-H1.
3.1. STRAP
Serine-threonine kinase receptor-associated protein (STRAP) is a
positive regulator of 3-phosphoinositide-dependent protein kinase-
1 (PDK1), andnegatively regulates TGF-b signaling by stabilizing the
interaction between TGF-b receptor and Smad7 [47]. A recent study
has shown that through interaction with STRAP, Nm23-H1 pro-
motes STRAP induced inhibition of TGF-b signaling, suggesting a
molecular link between TGF-b and Nm23-H1 regulated signaling
pathways [48]. Later, the same group also demonstrated thatReferences
y correlates with high expression of h-prune and [50,52,53]
y [48,49]
motility by controlling Ras-Raf-MEK-Erk pathway [38]
onuclease and tumor metastatic activity [43,45,59]
d [58,166]
and intercellular adhesion [55]
change factor for Cdc42, and blocks Nm23-H1 [56]
[57]
tatic potential of Nm23-H1; together EBNA3C and
nti-angiogenic activities. In cooperation with
a-V integrin expression levels
[13,61,104,105,123,134,146]
[13,103]
ocks KSHV induced cell invasiveness through [165]
y inhibiting Nm23-H1 multidirectional activities [155]
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with p53 and positively regulate its functions, including p53-in-
duced apoptosis and cell-cycle arrest, probably through inactivation
of Mdm2 functions [49].
3.2. H-prune
Another attractive Nm23-H1 binding protein that was identiﬁed
in humans is prune (h-prune) [50]. Elevated levels of h-prune
expression has been shown to be associated with a low expression
level of Nm23-H1 in aggressive breast carcinomas, suggesting an
inhibitory role for h-prune against themetastasis suppression func-
tion of Nm23-H1 [51]. Over-expression of h-prune in a breast cancer
cell line stimulated cellular motility, however abrogated by the
simultaneous expression of Nm23-H1 [52]. Other than breast can-
cer, h-prune expression has been correlatedwith tumor aggressive-
ness in gastric cancer and sarcoma [53,54]. Interestingly, a direct
correlation between an increase in h-prune phosphodiesterase
activity and cellular motility, as a result of a direct protein–protein
interaction with Nm23-H1, was found in the breast cancer model
[52]. Several speciﬁc chemical inhibitors of h-prune phosphodies-
terase activity have been shown to block tumor cell motility, sug-
gesting that these inhibitors could be used as ‘lead’ compounds in
development of additional therapies against cancermetastasis [52].
3.3. KSR
Other reported Nm23-H1 binding proteins include the kinase
suppressor of Ras (KSR), a scaffold protein for themitogen-activated
protein kinase (MAPK) cascade [38]. Nm23-H1 also interacts with
Tiam1 (T-cell lymphoma invasion andmetastasis 1), a speciﬁc guan-
ine nucleotide exchange factor for Rac1, and down-modulates
Tiam1-Rac1 mediated signaling [55]. The inhibitory effect of
Nm23-H1 on Tiam1 activity can lead to reduce cell motility and
intercellular adhesion [55]. Recently, we have shown that Nm23-
H1 also interacts with another member of the guanine nucleotide
exchange factor family,Dbl-1 [56]. This interaction results in the loss
of Dbl-1 function as a guanine nucleotide exchange factor for Cdc42,
thereby inhibiting the suppression of cellmotility byNm23-H1 [56].
Nm23-H1 was also shown to bind estrogen receptor a, which
resulted in an altered pattern of estrogen induced gene expression
[57]. Rad is theprototypicmember of a newclass of Ras-relatedGTP-
ases [58].Nm23-H1was shown to interactwithRad and functions as
a GTPase-activating protein for Rad [58].
3.4. SET
The DNA exonuclease activity of Nm23-H1 is likely to be central
to its metastasis suppressor function (discussed above). Nm23-H1
forms an inhibitory complex with SET, a critical protein complex
that can regulate a number of cellular pathways linked to tumori-
genesis and metastasis [59]. SET may modulate the potential
Nm23-H1 mediated exonuclease activity by sequestering Nm23-
H1 into the cytosol, thereby promoting metastasis [59]. Further
studies suggest that the DNA nicking activity may be due to the
co-puriﬁcation with another protein with nicking activity like
UDG [46] and the role of Nm23-H1 in this complex still needs to
be further explored.
To date, multiple important cellular proteins were identiﬁed as
Nm23-H1 binding partners as potential therapeutic targets
(reviewed in [60]). However, due to the sticky nature of Nm23 pro-
teins [60], excessive care is strongly suggested for investigators in
designing their experiments to minimize potential artifacts. Subse-
quent studies are necessary to further establish the functional
relevance to the binding activities, such as mutational analyses
to show a loss of the activity as well as biological consequencesdue to protein–protein interaction or in vivo studies using mouse
model systems.
4. Tumor viruses and Nm23-H1
A number of current studies have clearly suggested a critical
role for Nm23-H1 in the suppression of tumor virus induced cell
migration and cancer progression. Apparently this role is mediated
by protein–protein interactions between Nm23-H1 and tumor
virus encoded oncoproteins. Below, we discuss the current
thoughts on the multiple tumor viruses encoded oncoproteins that
associate and regulate Nm23-H1 associated functions to accelerate
cancer progression due to their pro-metastatic activities (Fig. 2).4.1. EBV and Nm23-H1
One of the best studied Nm23-H1 binding proteins is a latent
antigen, EBNA3C, encoded by Epstein–Barr virus (EBV) [61,62].
EBV is a lymphotropic gamma-herpes virus that asymptomatically
persists in greater than 90% of the world population [63–65]. How-
ever, EBV occasionally causes a self-limiting disease, infectious
mononucleosis in adolescents and has been found to be associated
with the development of several B-cell lymphomas and epithelial
cancers including Burkitt’s lymphoma, nasopharyngeal carcinoma,
Hodgkin’s disease, AIDS-associated and transplant-associated
immunoblastic lymphoma, and in some cases invasive breast car-
cinoma [13,63–65]. Recently, EBV has been shown to be related
to gastric carcinoma (GC) with an occurrence rate varying from
1.3% to 20.1% in different countries [66]. In vitro, EBV can efﬁ-
ciently transform quiescent B-cells into continuously proliferating
lymphoblastoid cell lines (LCLs) [63,65]. These latently infected
LCLs carry the viral genome as extra-chromosomal episomes that
express only a small subset of genes including six nuclear antigens
(EBNA-1, 2, 3A, 3B, 3C and LP), three integral membrane proteins
(LMP-1, 2A, and 2B), two non-translated RNAs (EBER-1 and -2)
and several microRNAs [63,65,67]. Genetic studies using recombi-
nant viruses established with a bacterial artiﬁcial chromosome
(BAC) system, from a number of different groups have shown that
EBNA-1, -2, -3A, -3C, -LP and LMP-1 are important for EBV medi-
ated transformation of naïve B-cells in vitro, indicating that a com-
plex cascade of molecular events is required to surpass normal
growth controls [67–71].4.1.1. EBNA1
EBNA1. is the only virus encoded antigen expressed in all EBV
associated tumors [72]. Although, the oncogenic potential of
EBNA1 in EBV-associated malignancies still remains elusive due
to differences in the results from a number of groups [73–75],
the importance of EBNA1 in EBV infection is unquestionable as
it is absolutely essential for the episomal maintenance and repli-
cation in latently infected cells [69,76]. EBV episomal stability
has been shown to be maintained through the interaction be-
tween EBNA1 and a cis-acting DNA element referred to as the
origin of plasmid replication (OriP). This is composed of two sep-
arate regions, the family of repeats (FR) and a dyad symmetry
(DS) element [77,78]. In addition to direct DNA binding ability
through the C-terminal domain, EBNA1 tethers the EBV genome
to metaphase chromosomes through two RGG-like motifs located
at the N-terminal DNA binding domain. However, the precise
mechanism through which EBNA1 is attached to the metaphase
chromosome is not completely understood [79–83]. EBNA1 is
composed of unique amino-terminal (residues 1–89) and car-
boxy-terminal (residues 328–641) domains ﬂanking a large Gly-
Ala with no clear biochemical function [84]. However, this repeat
region has a cis-acting capacity to suppress antigen presentation
Fig. 2. Tumor virus encoded oncoproteins can effectively modulate cancer metastasis by regulating Nm23-H1 associated activities. Following infection, tumor viruses
encoded oncoproteins (EBV EBNA3C and EBNA1; KSHV LANA and HPV E7) target multiple cellular pathways, including metastasis. The presence of different viral proteins
(EBNA1, EBNA3C and LANA) results in change in sub-cellular localization of Nm23-H1 from cytoplasmic to predominantly nuclear. In nucleus they form a stable complex.
Together with Nm23-H1, EBNA3C induces transcriptional up-regulation of several genes, inducing MMP-9, Cox-2 and a-V integrin. These activities further alter cellular
invasiveness and angiogenesis. Coupled with Nm23-H1, EBNA3C also rescues Necdin-mediated downregulation of its downstream promoter (VEGF). Necdin can interact with
Nm23-H1 that further modulates Nm23-H1 associated NDP kinase as well as protein kinase activities. HPV encoded E7 oncoprotein interacts with Nm23-H1 and blocks
granzyme A induced apoptosis, thereby promoting cell invasiveness.
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mune escape during EBV infection [85,86]. A number of studies
identiﬁed a high frequency of sequence variation at a region (res-
idues 466–527) within the DNA binding-dimerization domain of
EBNA1 [66]. EBNA1 was also shown to induce genomic instability
in malignant B-cells, as manifested by the occurrence of non-clo-
nal chromosomal aberrations, oxidative DNA damage and activa-
tion of the DNA damage response [87,88]. In addition, EBNA1 was
shown to regulate cellular gene expression and inhibits the
canonical NF-jB pathway by inhibiting IKK phosphorylation,
implicating a vital role for EBNA1 in the pathogenesis of naso-
pharyngeal carcinoma [89]. Moreover, EBNA1 expression in gas-
tric carcinomas cells was shown to be associated with
enhanced tumorigenicity [90]. A number of published studies
are consistent with a role for EBNA1 in proliferation of EBV-posi-
tive cells [91–93]. For instance, interference with EBNA1 function
in EBV-positive Burkitt’s lymphoma cells, by ectopic expression
of a dominant-negative EBNA1 mutant resulted in increased cell
death [91]. Similarly, down-regulation of EBNA1 expression in a
Burkitt’s lymphoma cell line or EBV-positive epithelial cells
by RNA interference exhibited reduction in cell proliferation
[92,93].4.1.2. EBNA3C
It has been proposed that EBNA-3A, -3B, and -3C genes likely to
be generated as a result of a series of gene duplication events [94].
They possess the same promoter, similar exons, codons, introns,
and a homologous N-terminal domain, which interacts with the
Notch-signaling mediator RBP-Jj, a sequence-speciﬁc DNA binding
transcription factor that mediates EBNA2 transcriptional up-regu-
lation [63,94–97]. Despite these similarities, EBNA3A, EBNA3B,
and EBNA3C have divergent roles in maintaining LCL growth, as
EBNA3B is dispensable, whereas both EBNA3A and EBNA3C are
absolutely required for LCL transformation [71,98]. Importantly,
EBNA3C can only co-activate the viral LMP1 promoter in accor-
dance with EBNA2 [99]. An EBNA3C SUMO interaction motif
(SIM) and a domain that interacts with the PU.1 transcription fac-
tor have been implicated in LMP1 promoter co-activation with
EBNA2 [99]. Conditional EBNA3C inactivation resulted in up-regu-
lation of both p16INK4A and p14ARF tumor suppressors, suggesting a
possible mechanism forEBNA3C mediated LCL growth regulation
[98]. Beside this, EBNA3C has been shown to interact with multiple
transcriptional regulators, including c-Myc, prothymosin a, his-
tone deacetylase 1 (HDAC1), CtBP, DP103, SMN, SCFSkp2, p300,
p53 and Nm23-H1as well as a number of important cell-cycle
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Chk2, implicating a complex regulatory role played by EBNA3C
during EBV mediated cellular transformation [64,100–102]. The
contribution of EBNA3C and Nm23-H1 to transcription regulation
was further explored by investigating the role of these proteins
on modulating transcription of Cox2, av-integrin and the metallo-
proteinase (refs).
4.1.3. Role of EBV antigens in Nm23-H1 mediated metastasis
The EBV encoded essential latent oncoproteins EBNA1 and EB-
NA3C have been shown to speciﬁcally interact with Nm23-H1
[61,103]. The signiﬁcance of these interactions was determined
in the nude mice model using cancer cells expressing the EBV anti-
gens and Nm23-H1 [13]. These in vivo studies showed that both
the EBV antigens promoted the growth of transformed cells; how-
ever and interestingly their expression was less important at the
later stage of tumor development [13]. As expected, the expression
of Nm23-H1 critically affected the growth of cancer cells and sup-
pressed their metastatic potential [13]. This effect was rescued by
the expression of either EBV antigens. The pro-metastatic potential
of EBNA3C was found to be higher when compared to EBNA1,
which triggered a dramatic immune response, as indicated by in-
creased spleen size and development of ascites in the mice [13].
This study was the ﬁrst report linked to tumor virus mediated
metastasis suppression during cancer development, and at least
in part widens the range of potential drug targets. Furthermore,
the molecular mechanisms by which these viral oncogenes func-
tions as pro-metastatic factors are still been investigated and stud-
ies along these lines should also yield more interesting possibilities
for targeted therapies against EBV associated cancers.
4.1.4. Anti-angiogenic activity of Necdin is blocked by EBNA3C coupled
with Nm23-H1
The block to the anti-angiogenic activity of Necdin by EBNA3C
and Nm23-H1 suggests another level of regulation through which
these viral antigens can modulate Nm23-H1 activities. The domain
of EBNA3C that speciﬁcally binds to Nm23-H1 has been previously
identiﬁed and lies within the region comprising residues 637–675
of EBNA3C, ﬂanked by the proline- and glutamine-rich domains
[104]. A Blast analysis of this domain sequence shows a consider-
able homology to a cellular protein, called Necdin [105]. Necdin be-
longs to the MAGE family of proteins, which are shown to have
multiple roles in different cellular processes, including cell-cycle
regulation as well as apoptosis [106]. The most signiﬁcant charac-
teristic of the MAGE family of proteins the possession of a large
central region which is referred to as the MAGE homology domain
(MHD), whereas their amino- and carboxy-terminal domains are
unique for the individual family members [106]. The sub-cellular
localization of Necdin in differentiated neurons has been previ-
ously demonstrated to be predominantly cytoplasmic, with a sali-
ent change in location to the nucleus under speciﬁc physiological
conditions [107]. Necdin was also shown to act as a cellular tran-
scription repressor by directly binding to multiple guanosine clus-
ters within the promoter region of target genes [108]. It has also
been suggested that Necdin can regulate transcription of other
genes engaged in multiple cellular events either through direct
binding with DNA or through its interaction with other transcrip-
tion factors, such as p53 and E2F1 [106,109]. Importantly, in the
context of cancer and tumor development, Necdin was shown to
interact with and modulate the activity of Hif-1a, a major tran-
scription regulator in hypoxia [110]. Thus, the regulation of Hif-
1a expression by Necdin may have important consequences,
including downstream effects on cell growth and proliferation
[110]. Subsequently, we have shown that EBNA3C together with
Nm23-H1 modulates the biological functions of Necdin in EBV
infected cells [105]. In this study, we showed that Necdin levelswere signiﬁcantly lower in EBV-positive cells [105]. EBNA3C affects
the sub-cellular localization of Necdin as well as rescues cells from
anti-angiogenic and anti-proliferative effects mediated by Necdin
[105]. Interestingly, both EBNA3C and Nm23-H1 were able to res-
cue not only Necdin-mediated transcriptional repression of the
downstream vascular endothelial growth factor promoter but also
its growth suppression and anti-angiogenic effects on cancer cells
[105]. The majority of these responses were mediated through res-
idues 191–222 of Necdin, known to be important for nuclear
matrix targeting [105]. This above study further suggests a novel
role for Necdin in regulation of downstream cellular targets in
virus-associated human cancers.
4.1.5. Cox-2 mediated inﬂammatory response is augmented by the
EBNA3C-Nm23-H1 complex
Similar to other tumor viruses, EBV is known to critically mod-
ulate the inﬂammatory response [63]. Prostaglandin (PG) G/H end-
operoxidase synthases, also known as cyclo-oxygenases (COX),
play a major role in inﬂammatory responses [111]. Among the
two isoforms of COX (1 and 2), the inducible COX-2 molecule is
highly stimulated in a variety of inﬂammatory diseases and in re-
sponse to pro-inﬂammatory cytokines, growth factors and other
tumor inducers [112–114]. Elevated expression of COX-2 has been
reported in many premalignant lesions and epithelial cancers, such
as colon cancer, lung cancer, breast cancer, gastric cancer, esopha-
geal cancer, and head and neck cancers, suggesting that COX-2
plays a critical role in development of these cancers [115–119].
Up-regulation of COX-2 in cancer cells has also been linked to in-
creased angiogenesis as well as cancer metastasis [120–122]. We
and others have shown that COX-2 is frequently expressed in
either EBV-positive nasopharyngeal tumors or detected at signiﬁ-
cantly higher levels in EBV-transformed LCLs, suggesting a role
for COX-2 in EBV pathogenesis [123,124]. The EBV encoded onco-
proteins, both LMP1 and EBNA3C, have been shown to up-regulate
COX-2 expression utilizing different mechanistic pathways
[123,124]. While, LMP1 induces COX-2 expression in an NF-jB-
dependent manner [124], EBNA3C was shown to accelerate COX-
2 expression and in cooperation with Nm23-H1 can signiﬁcantly
upregulate the expression [123]. Importantly, COX-2 was also
shown to play a role in de novo infection of various DNA and
RNA viruses, including herpes viruses, such as herpes simplex virus
(HSV), human cytomegalovirus (HCMV), EBV, and murine gamma
herpes virus 68 (MHV-68) [63,125]. Nonetheless, a comprehensive
study for COX-2 regulating EBV reactivation needs to be further ad-
dressed, particularly in cooperation with Nm23-H1. It would be
interesting to know if Nm23-H1 in the absence of viral antigens
can modulate Cox-2 expression with other cellular factors and
whether or not the virus can target these factors to enhance the
activities of these inﬂammatory molecules in EBV infected cells.
4.1.6. Regulation of metalloproteinases by the EBV essential latent
antigen EBNA3C
An important step in invasion and metastasis is degradation of
the basement membrane to enable tumor cells to escape from the
primary growth site [126]. The matrix metalloproteinase (MMP)
family of proteins is involved in the degradation of all components
of the basement membrane, and members of every family of
metalloproteinases have been implicated in malignancy and
metastasis [126]. The activity of MMPs is tightly controlled, with
regulation occurring mainly at the transcriptional level [126]. The
proteins are further regulated through activation of the pro-
enzyme and the tissue inhibitors of metalloproteinase [126]. A
number of MMPs have been found to be associated with cell migra-
tion and invasion, including MMP-2 and MMP-9, both of which
degrade type IV collagen [127,128]. The ability to degrade type
IV collagen, a major component of the basement membrane, indi-
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by degrading the basement membrane at sites of malignant tumor
growth [127,128]. Speciﬁcally, MMP-9 has been implicated as an
essential molecule required for tumor cell intravasation and
extravasation during metastasis [129].
EBV-immortalized B-cells have been shown to synthesize MMP-
9 and the addition of TIMP-1 to EBV-infected B cells has been
shown to inhibit their migration in vitro [130,131]. Moreover, a
number of studies have shown that EBV encoded LMP1 increases
cell invasiveness through augmenting MMP-9 expression level
[129,131–133]. LMP1-mediated MMP-9 expression occurs primar-
ily through the NF-jB and Ap1 signaling pathways [133]. Subse-
quently, we have demonstrated that EBNA3C in cooperation with
Nm23-H1 can induce MMP-9 expression at the transcript level as
well as increase in MMP-9 gelatinolytic activity [134]. As seen in
LMP1, speciﬁc mutations in the MMP-9 promoter showed that
the Ap1 and NF-jB binding sites are important for EBNA3C medi-
ated up-regulation [134]. This indicates that although these viral
antigens are distinctly different in both structurally and function-
ally, they share similar mechanistic pathway for exerting their
oncogenic properties.
4.1.7. The molecular association between Nm23-H1 and EBNA3C can
regulate integrins expression and cell migration
Integrins are heterodimeric molecules composed of a non-
covalently associated a- and b-subunit exclusively recognizing
ligands via an RGD amino acid sequence [135]. The ligands for
av integrins include vitronectin, bronectin, brinogen, von Wille-
brand factor and osteopontin [126,136–140]. Interestingly, av
integrins are expressed on migratory cells such as metastatic mel-
anomas and breast cancer cells and integrin expression correlates
with metastasis [141–143]. Additionally, aVb3 integrin is directly
associated with MMP2 on melanoma cells, which is thought to
provide tumor cells with the coordinated matrix degradation
and cellular motility, thus facilitating cellular invasion [144].
The role of Nm23-H1 in regulating a-V integrins has been poorly
understood, with exceptions in some clinical reports where inves-
tigators have tried to correlate Nm23-H1 expression with av inte-
grin level. Importantly, elevated expression of av integrins has
been shown to be associated with EBV mediated immortalization
of naïve B-cells [145]. Moreover, LMP-1, LMP-2 and EBNA-2
expression were shown to amplify av integrins expression levels
in LCLs [145]. In addition, we showed that through interacting
with Nm23-H1, EBNA3C can lead to an increase expression of
av integrin [146]. The study showed that Nm23-H1 alone
down-regulates av integrin expression in a dose responsive man-
ner, while in contrast, EBNA3C up-regulate av integrin expression
[146]. Furthermore, the study also showed that the association of
the Sp1 and GATA transcription factors with Nm23-H1 is required
for the transcriptional modulation of av integrin promoter activ-
ity [146].
These ﬁndings provide at least in part, if not the complete sce-
nario, potential molecular mechanisms which allows us to fur-
ther understand how EBNA3C can reverse the anti-migratory
effect of Nm23-H1 in virus infected cells. Thus, EBNA3C has
pro-metastatic properties through driving the upregulation of a
number of these cellular targets known to be critical for cell
migration and metastasis. These studies provide a framework
which demonstrates the complexity of the potential interacting
map which shows very clearly that EBV by using its essential
antigens can strategically target speciﬁc cellular promoters to
modulate their expression and so induce the transcription of
the genes and so result in greater activity. The consequences of
these activities are the enhanced metastatic potential of the viral
infected cells.4.2. HPV and Nm23-H1
The human papilloma viruses (HPVs) are the causative agents of
the most common sexually transmitted diseases that infect both
females and males [147,148]. HPVs commonly infect mucosal gen-
ital epithelia, with an estimated 75% of humans being affected dur-
ing life [149]. HPV infection is very common among men and
women across all geographical, racial and socio-economic sub-
group worldwide [148]. So far, more than a hundred different types
of HPV have been identiﬁed and approximately forty types can in-
fect the anogenital region [148]. Anogenital HPV types have been
further classiﬁed into ‘low-risk’, which are associated with anogen-
ital warts and mild dysplasia, and ‘high-risk’ types, which are asso-
ciated with high-grade dysplasia and anogenital cancers, such as
cervical and anal carcinoma [148,150]. The HPV genome is divided
into long control regions (LCR), which plays a role in regulating
gene expression and DNA replication; open reading frames (ORF),
which are involved in expression of the early gene proteins E1-
E8; and the late genes encoding structural proteins L1-L2 [63].
HPV encoded antigens are engaged in viral replication, cellular
transformation, checking viral as well as cellular gene transcrip-
tion, and also generation of viral progeny [63]. Through encoding
two major antigens, E6 and E7, HPV establishes cancer particularly
through the ubiquitin-proteasome mediated degradation of two
tumor suppressor proteins, p53 and pRb [63,151]. These two onco-
proteins, E6 and E7 also play a central role in virus reproduction as
well in inducing immortalization and transformation by re-pro-
gramming cell-cycle control in differentiating host epithelial cells
[151]. Through interacting with several important cellular pro-
teins, both E6 and E7 have been shown to induce genomic instabil-
ity and mitotic defects when introduced into cells [152]. The E7
oncoprotein is considered essential for ‘high-risk’ HPVs transform-
ing properties, while a cooperating role is played by its oncogenic
partner E6 [153,154]. Since E6 and E7 oncoproteins are critical but
not sufﬁcient for complete cellular transformation [151], addi-
tional genetic alteration is also required. A greater understanding
of the role of HPV antigens in cancer propagation will eventually
aid in the development of antiviral treatment, as well as unveil a
more general mechanism of HPV mediated oncogenesis.
Similar to EBNA3C, the HPV encoded E7 oncoprotein has also
been shown to interact with Nm23-H1 [155]. The results showed
that E7 expressing cells are resistance to Granzyme A-induced
apoptosis and promotes cell invasiveness [155]. The authors fur-
ther suggested that disrupting the multifunctional activity of
Nm23-H1 by E7 promotes cell transformation as well as tumor
progression [155]. It would be interesting to know whether or
not the activity of E7 and Nm23H1 can hold up in vivo using a
mouse model system similar to that shown for the EBV studies.
One would suspect that the same would hold true for most of
the antigens encoded by well-known tumor viruses.
4.3. KSHV and Nm23-H1
The Kaposi’s sarcoma-associated herpes virus (KSHV) is the eti-
ologic agent of Kaposi’s sarcoma (KS) [156]. Despite the reduced
incidence of HIV-associated KS in the era of highly active anti-retro-
viral therapy, KS is still considered to be one of the most common
HIV-associated tumors in the modern era and an important cause
of morbidity and mortality in patients receiving solid organ trans-
plants [157–159]. In addition to KS tumors, KSHV has also been
causally associated with two types of lymphoproliferative diseases,
primary effusion lymphoma (PEL) and multicentric Castleman’s
disease (MCD) [156,160]. Attainment of an invasive phenotype rep-
resents one of the major hallmarks of KSHV-infected cells and is
thought to be a key pathogenic mechanism for the development
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gely latent and during latency, only a small subset of viral genes is
expressed [63,156]. KSHV encoded latency-associated nuclear anti-
gen (LANA) is one of the crucial genes expressed during latency and
is necessary and sufﬁcient for episome persistence in the absence of
other virus encoded genes [63]. In addition to episomal mainte-
nance, LANA functions as a transcriptional modulator of numerous
cellular and viral promoters, including its own promoter [63,156].
LANAmediated transcriptional activation was extensively reported
to be accompanied by many cellular proteins including ATF, AP-1,
CAAT, and Sp1 [156]. LANA has also been shown to have transcrip-
tional repressive effects through interacting with many cellular co-
repressors including mSin3, SAP30, CIR, MeCP2 and SUV39H1
[156].
A large body of evidence supports a role for LANA in regulation of
many metastasis suppressor genes during KSHV-mediated patho-
genesis [162–164]. Recently, amore direct function for LANA in con-
nection with metastasis regulation has been established [165]. The
study showed that LANA augments expression as well as nuclear
translocation of Nm23-H1 [165] similar to that seen for the EBV
antigens EBNA1 and EBNA3C. The study also suggested that activa-
tionof theRas-BRaf-MAPKsignal transductionpathway, secretionof
pro-migratory factors associated with this pathway, and KSHV-in-
duced cell invasiveness are critically dependent on deregulation of
Nm23-H1 activity [165]. Interestingly, induction of cytoplasmic
expression of Nm23-H1 using a pharmacologic inhibitor of DNA
methylation has shown marked reduction in activation of KSHV-
associated Ras-BRaf-MAPK pathway and cell invasiveness, suggest-
ing a potential therapeutic approach against KSHV associated
human cancers [165].
The link between viral antigens and Nm23-H1 has clearly pi-
qued interest as a potential mechanism by which these tumor
viruses can also regulate the aggressiveness of the tumors. Viral
associated tumors are known to be highly invasive and when asso-
ciated with high risk types of tumor viruses including HPV 16 and
18 in cervical carcinomas or EBV associated nasopharyngeal carci-
nomas these tumors tend towards been more aggressive and inva-
sive (refs). It would be interesting to know whether or not these
tumors also have changes in the levels of Nm23-H1 and that they
can usurp the anti-metastatic functions of Nm23-H1 as pro-
metastatic agents.
5. Conclusion
Studies exploring the mechanisms important for the metastatic
process have advanced tremendously in the last two decades, lar-
gely due to the collaboration of a diverse cohort of investigators
who have focused their expertise within several disciplines. The
ultimate goal of these studies is to develop novel anti-metastatic
therapies which are based upon the mechanistic controls underly-
ing the metastatic process. Hence, a complete understanding of the
biological phenomena of metastasis suppressor genes and the cor-
responding proteins is fundamental to achieving this goal. Tumor
viruses encoded antigens not only can initiate the development
of certain types of cancers but are also critically engaged in prop-
agation of the primary tumors from the initial sites by targeting
several metastasis suppressor genes [61,63,155,165]. Thus, these
viral antigens could also serve as potential candidates in develop-
ment of prophylactic vaccination strategies and along with the
metastasis suppressor genes could also be critical for targeted ther-
apeutic development against tumor virus associated human can-
cers. Promising steps towards this goal have recently been taken.
For example, investigators have been able to restore the normal
expression of metastasis suppressor genes, speciﬁcally Nm23-H1,
in cancer cells [34,35]. Nonetheless, whether or not drug inducedactivation of metastasis suppressor genes can also be attained in
clinical trials remains one of the major open questions and is yet
to be elucidated.
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